Ann arbor, mich. , march 22, 2024 (globe newswire) -- esperion (nasdaq: Espr) today announced that the united states food and drug administration (fda) has approved broad new … Nexlizet is a combination of 2 medicines, bempedoic acid and ezetimibe.

Indication nexlizet is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic … Bempedoic acid, a component of nexlizet, is indicated: €¢ to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary … The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of nexlizet and nexletol, at an incidence of ≥2% and 0. 5% greater than placebo … Nexlizet is a prescription drug approved by the u. s. Food and drug administration (fda) to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular …

Nexlizet is a prescription drug approved by the u. s. Food and drug administration (fda) to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular …